September 14, 2009 (Durham, North Carolina) — Patients taking dronedarone (Multaq, Sanofi-Aventis) for prevention of recurrent atrial fibrillation (AF) are about half as likely to remain in sinus ...
July 7, 2011 (Paris, France) — Sanofi, maker of dronedarone (Multaq), has suspended its phase 3b trial of its antiarrhythmic drug due to an increase in cardiovascular events seen in patients ...
LONDON, March 30 (Reuters) - Sanofi-Aventis's heart drug Multaq has been recommended for limited use on Britain's state health service, after all, following a change of tack by the country's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results